Back to search
FDAFDA · Food and drugs·Recall number D-0364-2024

Clindamycin Phosphate, Topical Solution USP, 1%, 60 mL, Rx Only, Manufactured for and Distributed by: Marlex Pharmaceuticals, Inc., New Castle, DE 19720, NDC 10135-0691-61

Published March 13, 2024 · Recall initiated: February 20, 2024

Summary

FDA records drug Class III recall D-0364-2024, published March 13, 2024 and initiated February 20, 2024. Recalling firm: Contract Pharmaceuticals Limited Canada; Status: Ongoing; Reported quantity: 45,875 bottles; Lot: Lot #: 119466, 119467 Exp 04/2025; 120351 Exp 08/2025; 121712 Exp 11/2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective Container: Out of specification for weight due to a slow leakage at the 12-month stability timepoint.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Contract Pharmaceuticals Limited Canada
Distributor
Nationwide in the U.S. and Puerto Rico
Lot
Lot #: 119466, 119467 Exp 04/2025; 120351 Exp 08/2025; 121712 Exp 11/2025
Risk classification
Class III
Area (FDA)
drug
Country
Canada

Related recalls

Questions about this recall

Was Clindamycin Phosphate, Topical Solution USP, 1%, 60 mL, Rx Only, Manufactured for and Distributed by: Marlex Pharmaceuticals, Inc., New Castle, DE 19720, NDC 10135-0691-61 recalled?

Yes. FDA published recall D-0364-2024 on March 13, 2024. Reported hazard: Defective Container: Out of specification for weight due to a slow leakage at the 12-month stability timepoint.

What should I do if I have this product?

Voluntary: Firm initiated · Letter